What is the recommended evaluation and management for nodules that wax and wane in size?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 23, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Management of Waxing and Waning Nodules

Nodules that wax and wane in size require different management strategies depending on their location and characteristics, with thyroid nodules warranting repeat fine-needle aspiration biopsy (FNAB) based on ultrasound risk stratification, while pulmonary nodules that change size should be followed with serial CT imaging to distinguish benign inflammatory processes from malignancy.

Thyroid Nodules That Change in Size

When to Repeat FNAB

The 2022 SFE-AFCE-SFMN consensus provides clear guidance on nodule progression 1:

  • Significant size increase is defined as ≥20% growth in two of three dimensions
  • However, context matters critically:
    • A 20% increase in an 8mm nodule has different implications than the same percentage increase in a 4cm nodule
    • Growth in a predominantly cystic nodule is less concerning than growth in a solid nodule
    • Inter-operator variability in ultrasound measurements must be considered

Risk-Stratified Approach for Benign (Bethesda II) Nodules

For nodules with initial benign cytology, repeat FNAB is NOT routinely needed unless specific criteria are met 1:

  • EU-TIRADS 5 nodules (highly suspicious): Repeat FNAB recommended even if initially benign, as malignancy risk reaches 3% (versus 0.6% for EU-TIRADS 2-4)

    • Particularly if multiple high-risk features present: marked hypoechogenicity, taller-than-wide shape, microcalcifications, irregular margins

  • EU-TIRADS 3-4 nodules: Repeat FNAB only if:

    • Ultrasound characteristics change
    • Significant size increase occurs (with caveats above)

Non-Diagnostic (Bethesda I) Nodules

Repeat FNAB under ultrasound guidance for nodules >1cm with EU-TIRADS 3,4, or 5 1:

  • Minimum interval: 1-3 months between attempts
  • If second FNAB remains non-diagnostic: consider core-needle biopsy
  • Emergency exception: Rapid growth with clinical suspicion of aggressive cancer requires urgent repeat FNAB or immediate biopsy if anaplastic thyroid cancer suspected

Pulmonary Nodules That Change in Size

Solid Nodules >8mm

For nodules that demonstrate growth or size changes 2:

Serial CT surveillance intervals 2:

  • 3-6 months
  • 9-12 months
  • 18-24 months
  • Then annually depending on clinical judgment

Use thin-section, non-contrast, low-dose CT techniques

Ground Glass (Nonsolid) Nodules

These nodules characteristically can wax and wane 3:

  • ≤5mm: No further evaluation needed 3
  • >5mm: Annual CT surveillance for at least 3 years 3
  • Key caveat: Nodules that develop a solid component or show true growth are often malignant and require further evaluation or resection

Part-Solid Nodules

These require more aggressive surveillance 3:

  • ≤8mm: CT at 3,12, and 24 months, then annual surveillance for 1-3 additional years
  • >8mm: Repeat CT at 3 months, then consider PET, biopsy, or surgical resection if persistent

Critical Pitfalls to Avoid

  1. Measurement variability: Changes in nodule size may reflect measurement error rather than true growth, especially with different operators or techniques

  2. Cystic versus solid composition: Size changes in predominantly cystic lesions (thyroid or pulmonary) are less concerning than changes in solid components

  3. False reassurance from stability: Small malignant nodules can appear stable on short-term follow-up, which is why extended surveillance (2+ years for pulmonary, ongoing for thyroid) is necessary

  4. Ignoring morphology: In both thyroid and pulmonary nodules, appearance matters as much as size—suspicious features should lower the threshold for intervention regardless of size changes

Differential Diagnosis for Waxing/Waning Pattern

While following the surveillance algorithms above, consider these specific etiologies that characteristically cause fluctuating nodule size:

  • Pulmonary: Tuberculosis 4, vascular Ehlers-Danlos syndrome 5, amiodarone toxicity 6, organizing pneumonia
  • Thyroid: Hemorrhage into nodule, inflammatory/infectious processes, colloid cyst changes

The waxing and waning pattern itself does not exclude malignancy—both thyroid and lung cancers can demonstrate size fluctuations, particularly with hemorrhage or inflammation.

References

5
Research

[Waxing and waning pulmonary nodules and cavities].

Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases, 2022

Related Questions

What is the minimum recommended duration of antimicrobial therapy for a deep puncture wound?
A 10‑day postpartum woman presents with dysuria and a urine culture growing mixed microbiota >100,000 CFU/mL; how should this be managed?
What is the appropriate 10‑day antibiotic regimen for a patient undergoing ENT follow‑up after image‑guided fine‑needle aspiration/biopsy, assuming no documented β‑lactam allergy?
In a 10‑month‑old infant with a slightly indented coronal suture, normal fontanelles, and appropriate head growth, what is the appropriate next step in management?
Should an asymptomatic urine culture with 10,000–49,000 CFU/mL Escherichia coli be treated?
What alternative antihypertensive medications can be used instead of amlodipine in a breastfeeding mother?
Can hernia repair cause increased intra‑abdominal pressure or abdominal compartment syndrome if the closure is performed too tightly?
What is the appropriate evaluation and treatment for a patient with childhood‑onset hair loss who denies hair pulling (suspected trichotillomania)?
Is there a relationship between exercise and outcomes in premenopausal breast cancer patients?
What is the appropriate management for a patient with peripheral edema possibly caused by a calcium‑channel blocker?
Can a patient with less than 50% arterial stenosis but diffuse arterial calcification develop critical limb ischemia?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.